Lupin MD on a biosimilars play fused around Japan 'anchor'
This article was originally published in Scrip
Executive Summary
Lupin may have been slow off the block in the biosimilars space in emerging markets compared with some of its Indian peers, but the Mumbai-based firm is hoping that a strategy centred around its "anchor market" Japan may more than compensate as well as propelling its entry into the US and Europe.
You may also be interested in...
Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market
Lupin and partner Yoshindo have sought marketing authorization for their biosimilar Enbrel in Japan. While not the first biosimilar etanercept in Japan, the NDA is seen opening up multiple opportunities for Lupin as it transitions to “higher complexity” products.
Lupin-Yoshindo Stake Claim For Play In Japan Biosimilar Enbrel Market
Lupin and partner Yoshindo have sought marketing authorization for their biosimilar Enbrel in Japan. While not the first biosimilar etanercept in Japan, the NDA is seen opening up multiple opportunities for Lupin as it transitions to “higher complexity” products.
Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge
After a bruising financial third quarter in which net quarterly profit plunged 65%, Lupin reported “a successful outcome” for clinical trials of its rheumatoid arthritis drug etanercept, its first biosimilar product for the global market.